Analystreport

Revance Therapeutics, Inc. (NASDAQ: RVNC) is now covered by analysts at Barclays PLC. They set a "buy" rating and a $31.00 price target on the stock.

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com